Citius Oncology stock analysis
Want to see CTOR full AI Analyst Report?
Citius Oncology (CTOR) Stock Price & Analysis
CTOR Stock Chart & Stats
- Day’s Range
- $0.53 - $0.58
- 52-Week Range
- $0.49 - $1.83
- Previous Close
- $0.57
- Volume
- N/A
- Average Volume (3M)
- 133.81K
- Market Cap
- $49.74M
- Enterprise Value
- $63.79M
- Total Cash (Recent Filing)
- $16.56M
- Total Debt (Recent Filing)
- $10.21M
- Price to Earnings (P/E)
- ―
- Beta
- 2.92
- Next Earnings
- Dec 17, 2026 (Est.)
- EPS Estimate
- -0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
LYMPHIR Demand Growth
Rapidly increasing wholesaler purchases and institutional participation indicate that LYMPHIR is gaining commercial traction beyond an initial launch. If this ordering pattern persists, it can build a broader prescribing base and create a foundation for recurring product revenue over the next several quarters.
Expanding Market Access
Broad institutional availability, formulary inclusion, and near-universal payer coverage reduce practical barriers to treatment adoption. These access characteristics support continued account expansion and improve the likelihood that commercial demand can translate into sustained patient starts and repeat orders.
Low Financial Leverage
Very low leverage gives Citius Oncology more balance-sheet flexibility than a highly indebted development-stage company. Although it remains loss-making, limited debt reduces interest and refinancing pressure, allowing management to direct more resources toward commercialization and clinical development.
Bears Say
Persistent Operating Losses
The company has not yet established a reported annual revenue base in the provided financial periods, while operating losses have widened substantially. This creates a fragile earnings profile in which future financial performance depends heavily on successful commercialization and rapid conversion of launch activity into revenue.
Increasing Cash Burn
Worsening operating and free cash flow indicate that the business is consuming increasing amounts of cash while building its commercial platform. Unless product revenue improves materially, continued burn may require additional financing and could constrain investment or dilute existing shareholders.
Nasdaq Compliance Risk
The compliance extension postpones rather than resolves the listing issue. Failure to regain the required bid price could begin a delisting process, potentially reducing market access and liquidity and complicating the company’s ability to use its public listing for future financing.
Citius Oncology News
Buy Rating Reaffirmed on Lymphir’s Growing Commercial Momentum and CTCL Market Upside; $4 Price Target Maintained
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Citius Oncology yesterday and set a price target of $4.00. Michael Okunewitch has given his Buy rating due to a
CTOR FAQ
What was Citius Oncology’s price range in the past 12 months?
What is Citius Oncology’s market cap?
When is Citius Oncology’s upcoming earnings report date?
How were Citius Oncology’s earnings last quarter?
Is Citius Oncology overvalued?
Does Citius Oncology pay dividends?
What is Citius Oncology’s EPS estimate?
How many shares outstanding does Citius Oncology have?
What happened to Citius Oncology’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Citius Oncology?
What is the TipRanks Smart Score and how is it calculated?
Citius Oncology Stock Smart Score
Company Description
Citius Oncology
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Leonard L. Mazur
- Employees
- 285
- Website
- www.citiusonc.com/overview/default.aspx
- Address
- 11 Commerce Drive, Cranford, NY, 07016, US
Citius Oncology (CTOR) Earnings & Revenues
CTOR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |









